EyeYon

What EyeYon does

EyeYon Medical is an Israeli ophthalmic medical device company founded in 2011 that develops synthetic biomaterial implants and drug-delivery contact lenses to treat corneal diseases. Its flagship product, EndoArt®, is the world's first synthetic corneal endothelial implant, manufactured from sterile biocompatible acrylic hydrophilic material. The device attaches to the posterior corneal surface to prevent fluid ingress and inhibit edema, offering a 3-year-shelf-life alternative to human donor tissue and eliminating graft rejection risk. The company also markets Hyper-CL™, a CE-marked therapeutic soft contact lens that functions as the first ocular drug depot system, increasing corneal contact time and bioavailability of topical therapeutics. Clinical evidence supports the platform: documented outcomes include a 28% reduction in central corneal thickness, visual acuity improvement from 2.13 to 1.84 logMAR, and a 90% long-term adherence rate in 4.5-year follow-up studies.

The company's business model is direct hardware sales of EndoArt and Hyper-CL devices to corneal surgeons and hospitals through a limited market release strategy, with pricing not publicly disclosed. EndoArt is commercially available across 12 countries (predominantly EMEA plus Japan) following CE approval, while Hyper-CL is commercialized in Europe and Asia. The customer base consists of individual high-volume corneal surgeons and major ophthalmic centers, with peer-to-peer surgeon education, conference presence (ESCRS, EUCornea, ASCRS), and peer-reviewed clinical publications serving as primary go-to-market channels.

In December 2025, EyeYon secured FDA Investigational Device Exemption (IDE) approval to initiate U.S. clinical studies of EndoArt, opening the largest near-term market opportunity. The company is led by founders Nahum Ferera (CEO), Dr. Ofer Daphna (Medical Director), and Prof. Arie Marcovich, with a senior commercial team including Charles Holmes (CCO, ex-Allergan VP of Ophthalmology) and has raised approximately $38M across five funding rounds since inception, most recently a $25M Series C in March 2021 led by CR-CP Life Science Fund.

Name

EyeYon

Legal name

EyeYon Medical LTD

Website

https://eye-yon.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

1–10 employees

Short description

EyeYon Medical is an Israeli ophthalmic device company that develops and commercializes EndoArt®, the world's first synthetic corneal implant for chronic corneal edema, and Hyper-CL™, a therapeutic contact lens drug-delivery platform, sold directly to corneal surgeons across 12 countries.

Ownership category

akta.pro rank

Product category

Ophthalmic Medical Devices

NAICS

Ophthalmic Goods Manufacturing (339115)

SIC

Surgical & Medical Instruments & Apparatus (3841), Ophthalmic Goods (3851)

akta.pro primary industry

Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery) (HLAHAJAK)

akta.pro secondary industries

Contact Lenses & Care Systems (Soft/RGP/Scleral Lenses; Cleaning/Disinfection Solutions) (HLAHAJAE), Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL), Cornea, External Disease & Refractive Surgery (LASIK/PRK) (HLAKAKAF)

Keywords

• Ophthalmic medical devices
• Corneal implants
• Corneal edema treatment
• Synthetic biomaterials
• Therapeutic contact lenses

Headquarters

HQ city

Jerusalem

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Others

Revenue model

1. Medical Device Sales - EndoArt: Revenue generated from commercial sales of EndoArt synthetic corneal implants to hospitals and surgeons. EndoArt is CE-approved and commercially available in Europe, with over 600 successful implantations worldwide since limited market release in September 2023.
2. Medical Device Sales - Hyper-CL: Revenue from Hyper-CL therapeutic contact lens product, which is CE-approved for continuous wear and in commercialization stage across Europe and Asia.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

EyeYon Medical develops and commercializes innovative ophthalmic medical devices. Its flagship product, EndoArt®, is the world's first synthetic corneal endothelial implant used as an alternative to human donor tissue for treating chronic corneal edema. The company also commercializes Hyper-CL™, a therapeutic soft contact lens designed as an ocular drug depot that increases the contact time and bioavailability of topical eye-drop medications on the cornea.

Product overview

EyeYon Medical is an ophthalmic medical device company with two core products: EndoArt®, the world's first synthetic implant for treating chronic corneal edema (serving as an artificial endothelial layer), and Hyper-CL™, a therapeutic contact lens that acts as an ocular drug depot to enhance topical drug bioavailability. Both products are CE-approved, with EndoArt® commercially available in Europe and Hyper-CL™ commercialized across Europe and Asia. The company is pursuing FDA approval for EndoArt® through U.S. clinical trials.

Differentiator

Problem solved

Functional benefit

Brands

• EndoArt®: The world's first synthetic implant for treating chronic corneal edema, serving as an artificial endothelial layer.
• Hyper-CL™

Products and services

• EndoArt® EndoArt® is the world's first synthetic corneal implant designed to treat chronic corneal edema. It serves as an artificial endothelial layer that attaches to the back of the corneal surface, preventing fluid transfer into the cornea and inhibiting edema buildup. Made of sterile biocompatible acrylic hydrophilic material with a 3-year shelf life, it is intended for hospitals and cornea surgeons performing corneal transplant procedures as an immediately available alternative to human donor tissue, with no rejection risk.
• Hyper-CL™ Hyper-CL™ is a CE-approved therapeutic soft contact lens that functions as an ocular drug depot system. It is designed to increase the contact time of topical eye drops on the cornea, thereby improving treatment efficacy for various corneal conditions and post-surgical healing. Indicated for short-term continuous wear up to 7 days to promote corneal healing and relieve corneal pain, it is commercialized across Europe and Asia for ophthalmologists and eye surgeons.

Quantifiable outcome

• 28% reduction in central corneal thickness (844 μm to 607 μm) within 1-6 months post-surgery
• +3 more outcomes

Named customers7 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Athens Vision (Greece)coreChannel Partner/ Reseller/ DistributorFirst EndoArt implantation in Greece performed at Athens Vision, marking entry into new market in southeastern Europe. Dr. Anastasios Charonis and team joined the mission to bring EndoArt to Greek patients.
• Ophthalmology Futures ForumminorStrategic or Co-development PartnerEyeYon Medical presented at Ophthalmology Futures Forum in Copenhagen, sharing milestones and vision for the future of corneal disease treatment with device- and cell-based therapies.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Ocular Therapeutix: Ocular drug-delivery company with sustained-release intracanalicular and punctal plug platforms — closely comparable to EyeYon's Hyper-CL ocular drug depot concept, although focused on the posterior segment/glaucoma market.
• Kala Bio: Clinical ophthalmology company developing novel therapies for rare eye diseases — comparable as a small-cap ophthalmic-specialty developer navigating regulatory and commercial milestones in a niche indication.
• Trefoil Therapeutics: Clinical-stage biotech developing engineered FGF-1 protein therapy (TTHX1114) for corneal endothelial disease and other corneal disorders — competing modality in the same therapeutic indication as EndoArt.
• TissueTech / Bio-Tissue: Regenerative ophthalmology company selling amniotic membrane and other ocular surface products — overlaps with EyeYon's corneal surface and anterior-segment therapeutic categories.

Broad incumbents

• Glaukos Corporation: Public ophthalmic medical device company with a broader MIGS and corneal health pipeline; relevant comparable for surgical-device commercialization, regulatory pathway, and ophthalmic-surgeon sales model in EyeYon's target market.
• Nicox SA: Specialty ophthalmology company developing therapeutics for ocular surface and anterior-segment diseases — comparable as a small-cap, commercial-stage ophthalmology business in adjacent indication space.

Direct peers

• CorneaGen: Leading corneal tissue provider for transplantation, serving as the incumbent donor-tissue alternative that EyeYon's EndoArt directly displaces. Both companies serve corneal surgeons treating endothelial disease.
• Aurion Biotech: Clinical-stage cell therapy company developing allogeneic corneal endothelial cell therapy for corneal edema — the most direct competing approach to EyeYon's EndoArt, targeting the same endothelial disease patient population.
• KeraMed (VisionGift/KeraMed): Corneal tissue and eye-bank organization providing donor corneas for transplant — the established supply-side incumbent whose availability EndoArt is engineered to bypass.
• SightLife (Lions VisionGift): Non-profit eye-bank providing donor corneal tissue globally — represents the status-quo supply chain for corneal transplantation that EndoArt is designed to supplement or replace.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/EyeYon
• LinkedInlinkedin.com/company/eyeyon-medical

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EyeYon